Preventing RSV in Babies: A Scientific Milestone
- Paul Offit
Access Resources
About
This 3-minute video discusses the use of nirsevimab (Beyfortus™) to protect vulnerable infants from RSV. Dr. Paul Offit explains its benefits, clinical trial results, and eligibility criteria. Nirsevimab is not a vaccine but an antibody that helps protect against RSV for at least five months. It is recommended for all babies under 8 months before the RSV season and high-risk children aged 8 to 19 months. The drug aims to reduce hospital visits during winter when RSV cases are high.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.